[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contraception-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contraception-use":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100639585","flo-digital-contraceptive-study-100639585",false,"NCT07630064","Flo Digital Contraceptive Study","Flo Digital Contraceptive Study: Safety and Effectiveness of Flo's Personalized Fertility Awareness Tool for Preventing Pregnancy","FDC","Inclusion Criteria:\n\n* Adults with female reproductive organs aged ≥18 years\n* Reside in the United States of America\n* Have menstrual frequency (i.e., interval between first day of bleeding each cycle) between 16-90 days\n* Sexually active, having vaginal sex with male partner(s) without known fertility problems AND where neither partner has a known, or is at high risk of, sexually transmitted infections (STIs).\n* Desiring contraception, i.e., planning to prevent pregnancy and not currently trying or planning to conceive for at least 12 months, and up to 18 months. from enrollment\n* Willing and able to use FDC as advised, including ability to:\n* (1) Abstain from penile-vaginal intercourse on days indicated as \"Use protection\" OR\n* (2) Use barrier methods (such as condoms) for penile-vaginal intercourse on days indicated as \"Use protection\"\n* Possession of an iOS mobile device (version 16 or higher) with internet connectivity\n* Sufficient English language proficiency and knowledge of English language required for correct use of the intervention and mobile device\n* Willing to wear a functional Apple Watch capable of sensing wrist-skin temperature (Series 8 or later, Ultra) while sleeping, with it connected and sharing temperature data to the Flo application\n* No known pregnancy at the time of enrollment\n* Willing and able to provide valid consent\n\nExclusion Criteria:\n\n* Current use of any contraceptive medication, implant or technique, including but not limited to:\n* Oral contraceptive pills\n* Hormonal implants, injections, vaginal rings or transdermal patches\n* Intrauterine devices (copper and\u002For levonorgestrel)\n* Surgical sterilization (tubal ligation, salpingectomy, intrafallopian tube coils)\n* ≤12 weeks postpartum (second or third trimester pregnancy)\\*\n* \\*Includes terminations of any pregnancy \\>14 weeks OR have given birth \\>12 weeks postpartum without return of at least one menses\n* Postabortion (first trimester miscarriage, ectopic, termination) who have:\n* History of cycles outside the 21-35 day range, OR\n* Not had return of at least one menses following the abortion\n* Currently lactating (breastfeeding, pumping or otherwise), regardless of interval since last pregnancy\n* Had fewer than 9 menstrual cycles in the past 12 months\n* Have received medical advice from a healthcare provider that pregnancy is medically contraindicated, irrespective of whether this is due to a medical condition or risk, or due to medication being taken, or other reason.\n* Participants must be willing to NOT use condoms for penile-vaginal intercourse. Those who are unable or unwilling to restrict use of condoms for penile-vaginal intercourse for any reason, including but not limited to compromising health and\u002For safety of self or others will be excluded\n* Note: Use of barrier contraceptive for sexual encounters that could not result in pregnancy, such as oral or anal sex, is not restricted\n* Any condition or circumstance that, in the opinion of the Lead Investigator (LI) or designee, would compromise the participant's ability to comply with the study protocol, pose an unacceptable risk to the participant's safety or well-being, or interfere with the evaluation of study objectives\n* Concurrent participation in another research study that aims to prevent pregnancy\n* Extreme shift work patterns (e.g., unpredictable or rotating shifts changing more frequently than weekly, frequent time zone changes) that prevent consistent sleep schedules necessary for reliable temperature measurement","FEMALE","18 Years",{"count":20,"type":21},3800,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if the Flo Digital Contraceptive (FDC) app can effectively prevent unintended pregnancy in women aged 18 years and older residing in the United States. The main questions it aims to answer are:\n\nWhat is the rate of unintended pregnancy in women aged 18-35 years using FDC as their sole method of contraception under typical-use conditions, measured using the Pearl Index? What is the cumulative probability of unintended pregnancy over 13 menstrual cycles for all participants, including those with regular and irregular cycles?\n\nParticipants will:\n\nUse the Flo Digital Contraceptive app in 'prevent pregnancy' mode as their primary method of contraception for up to 13 menstrual cycles or 18 months, whichever comes first Wear an Apple Watch (Series 8 or later, or Ultra) while sleeping to collect nightly wrist temperature data, which the app uses to detect ovulation Log menstrual cycles, sexual activity, and any use of emergency contraception directly in the Flo app Complete monthly electronic surveys (ePROs) administered by the study team covering pregnancy status, adherence, safety, and experience Complete a baseline demographic survey at enrollment and an exit survey at the end of participation",[27],"Contraception Use","RECRUITING","2026-06-01",{"date":31,"type":32},"2026-06-05","ACTUAL",{"date":34,"type":32},"2026-04-22",{"date":36,"type":21},"2028-01-10",{"name":38,"class":39},"Flo Health Inc.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100637786","prospectivefemaleaya---late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100637786","NCT07622420","ProspectiveFemaleAYA - Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes (ProspectiveFemaleAYA)","FemFertilAYA","Inclusion Criteria:\n\n* Female cancer patients aged between 15 and 39 years at diagnosis.\n* Receiving a diagnosis of primary cancer 01\u002F01\u002F2025 or later\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For gynaecological surgery.\n* Detailed information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis.\n* Treated by surgery alone (except gynaecological surgery).\n* Patients with relapse or secondary malignant neoplasms at time of inclusion or having received already treatments for cancer\n* Adult individuals subject of a measure of legal protection and\u002For patients with severe mental disorders.","15 Years","39 Years",{"count":52,"type":21},3000,"OBSERVATIONAL","In the past two decades, the evidence-based knowledge on the prevalence and risk factors for gonads impairment, including infertility, following cancer and numerous cancer treatment regimen has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility and pregnancy potential, including the use and success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex as more recent treatment regimen have continuously also implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questionsis highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale registry of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian dysfunction and\u002For fertility impairment and premature ovarian insufficiency following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Fhormonal treatment and patients' satisfaction related to these procedures in Europe will be analysed to support patient-centric care.\n\nReproductive health counselling should not be limited to evaluating the risk of gonadotoxicity and offering fertility preservation to those at risk. It should also include evaluating the impact on post-treatment sexuality, menopausal symptoms management, and the counselling on contraception.\n\nIn addition to clinical information, whole genome sequence data will be generated for selected study participants with evidence of varying impact of gonadotoxic therapies on reproductive function to find genetic variants associated with risk of reproductive and organ toxicity.\n\nThe data collection will focus on all different cancer diseases, including diseases which are less common such as different types of sarcomas. This will be a significant development to the current state of information in existing registries.\n\nThe primary objectives of this prospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n1. To establish a database with relevant clinical characteristics at time of diagnosis, cancer therapy received and post-cancer clinical and reproductive outcomes by following AYA cancer patients longitudinally.\n2. To evaluate the effect of cancer therapies on ovarian function and reproductive potential.\n3. To evaluate fertility preservation measures performed, their risks and efficacy.\n4. To evaluate the impact of fertility preservation measures on the risk of cancer relapse.\n5. To evaluate occurrence of pregnancies\u002Flive births naturally conceived (including unplanned) or through medical assistance post-cancer and the obstetrical complications and neonatal health following the use of cryopreserved oocytes or gonadal tissue.\n6. To set up a genetic database based on whole genome sequencing of AYAs of the cohort. For this objective a Substudy 1 : \" Development of risk prediction models based on clinical and genetic data \" will be conducted.\n7. To develop prediction models for organ toxicities in cancer patients (objective included in Substudy 1).\n8. To evaluate the effect of cancer therapies on sexuality and quality of life. For this objective a Substudy 2 : \"Sexual Health\" will be conducted.\n9. To evaluate the use and counselling on contraception. For this objective, a Substudy 3 : \"Contraception\" will be conducted.\n10. To describe management of treatment-induced premature ovarian insufficiency (POI) and menopausal symptoms. For this objective a Substudy 4 \"Management of POI and Menopause Symptoms\" will be conducted.\n11. To explore patient's satisfaction receiving counseling and\u002For undergoing fertility preservation. For this objective a Substudy 5 on \"Satisfaction with Fertility Preservation\" will be conducted.",[56,57,58,59,60,61,62,63,27],"Cancer","Cancer in Pregnancy","Infertility","In Vitro Fertilisation (IVF) Treatment","Late Effects","Quality of Life","Sexual Health Quality of Life","POI",[65,66,67,68],"cancer therapy induced late effects","AYA cancer survivors","infertility as a late effect of cancer","late effects prediction","NOT_YET_RECRUITING","2026-05-27",{"date":72,"type":32},"2026-06-03",{"date":29,"type":21},{"date":75,"type":21},"2035-05-31",{"name":77,"class":78},"Karolinska Institutet","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100607941","phase-1-sildosin-as-a-male-contraceptive-non-hormonal-100607941","NCT07195097","Sildosin as a Male Contraceptive Non Hormonal","A Prospective Study to Evaluate the Efficacy of Silodosin 8 mg as an on-Demand, Reversible, Nonhormonal Oral Contraceptive for Males:","Inclusion Criteria:\n\n* male sexually active\n\nExclusion Criteria:\n\n* male on oral contraceptives Male with female partner on contraceptives","MALE","20 Years",{"count":89,"type":21},200,[91],"PHASE1","In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.",[27],"2025-09-25",{"date":96,"type":32},"2025-09-26",{"date":98,"type":21},"2025-09",{"date":100,"type":21},"2025-12",{"name":102,"class":78},"Benha University"]